Trial tests transplant using a half-matched donor for high-risk leukemia
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1 trial tests a special bone marrow transplant using a related “half-matched” donor (haploidentical), without a specific immune-suppressing medicine (“IS-free”). It’s for adults with certain high-risk AML or MDS to see if this approach can improve control of the disease while tracking safety.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have AML or MDS that fits one of the study risk groups (including specific “TP53” mutation patterns or very high-risk features).
- Your cancer was diagnosed or confirmed recently (within the last 4 weeks) for the group that allows prior treatment.
- You have a related half-matched donor (matched for key tissue markers: A, B, C, and DRB1) who is 18–65 years old.
- Your age fits your risk group: up to 65 for some groups, up to 75 for the TP53 ultra-high-risk group.
- Your body can handle intensive treatment: good heart, lung, liver, kidney function, and you’re well enough to be active most of the day (ECOG 0–2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a low-intensity bone marrow/stem cell transplant using a matched donor plus two medicines to help prevent the donor cells from attacking you. It aims to treat certain blood cancers—especially when standard treatment has not fully worked or when you are in remission but at higher risk.
This trial compares two reduced-intensity conditioning regimens before you receive stem cells from a donor who matches your HLA type. It aims to find which approach works better and is safer for certain blood cancers.
This study looks at using a “half-matched” stem cell transplant (haploidentical transplant) in adults around your age with acute leukemia or MDS. It may help people who cannot find a fully matched donor, but are still eligible for this type of transplant.
This trial tests a new way to do a stem cell transplant for people with hard-to-treat blood cancers. It combines a half-matched family donor (haploidentical) with a cord blood unit to help the transplant work better.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
This trial studies a specific type of partially matched (haploidentical) stem cell transplant in children with ALL, AML, or MDS. It looks at whether using certain immune system gene patterns (KIR) and measuring leftover disease after treatment can improve outcomes and cost-effectiveness.
Hear when a new Stem Cell Transplant Complications trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.